| Gilead Sciences, Inc. – Product Pipeline Review – 2012 |
| Publication Date |
May 2012 |
| Publisher |
Global Markets Direct |
| Product Type |
Report |
| Pages |
261 |
| Single User License |
$
500.00 |
| Site User License |
$
1000.00 |
| Corporate User License |
$
1500.00 |
|
|
Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase. |
Gilead Sciences, Inc. – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “Gilead Sciences, Inc. - Product Pipeline Review - 2012” provides data on the Gilead Sciences, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Gilead Sciences, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Gilead Sciences, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Gilead Sciences, Inc. - Brief Gilead Sciences, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Gilead Sciences, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Gilead Sciences, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Gilead Sciences, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Gilead Sciences, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Gilead Sciences, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Gilead Sciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Gilead Sciences, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Gilead Sciences, Inc. and identify potential opportunities in those areas.
Keyword
Current R&D Portfolio of Gilead Sciences, Inc.; Gilead Sciences, Inc. - Key Therapeutics; Gilead Sciences, Inc. - Pipeline Overview and Promising Molecules; Gilead Sciences, Inc. - News; Gilead Sciences, Inc. - Latest Updates; Gilead Sciences, Inc. - Pipeline; Gilead Sciences, Inc. - Discontinued/Dormant Projects
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 6
Gilead Sciences, Inc. Snapshot 7
Gilead Sciences, Inc. Overview 7
Key Information 7
Key Facts 7
Gilead Sciences, Inc. – Research and Development Overview 8
Key Therapeutic Areas 8
Gilead Sciences, Inc. – Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products – Monotherapy 13
Pipeline Products – Combination Treatment Modalities 14
Gilead Sciences, Inc. – Pipeline Products Glance 15
Gilead Sciences, Inc. – Late Stage Pipeline 15
Gilead Sciences, Inc. Clinical Stage Pipeline Products 17
Gilead Sciences, Inc. – Drug Profiles 20
Aztreonam 20
BI 224436 22
Cobicistat 23
Cobicistat + Prezista 24
GS 1101 + Bendamustine 25
GS 1101 + Bendamustine + Rituximab 26
GS 1101 + Fludarabine 28
GS 1101 + Ofatumumab 29
GS 6624 30
GS 9256 + GS 9190 + Ribavirin 32
GS 9256 + Pegasys + Copegus 34
GS-1101 36
GS-1101 + Rituximab 38
GS-5885 40
GS-6620 42
GS-7340 43
GS-7977 44
GS-7977 + Pegasys + Copegus 46
GS-9256 + GS-9190 48
GS-9451 49
GS-9451 + GS-5885 + Peginterferon Alfa 2a + Ribavirin 50
GS-9620 52
GS-9669 53
JTK-303 54
Quad 59
Ranexa 61
Ranolazine + Dronedarone 62
Truvada 64
Viread 66
Gilead Sciences, Inc. – Pipeline Analysis 67
Gilead Sciences, Inc. – Pipeline Products by Therapeutic Class 67
Gilead Sciences, Inc. – Pipeline Products By Target 69
Gilead Sciences, Inc. – Pipeline Products by Route of Administration 71
Gilead Sciences, Inc. – Pipeline Products By Mechanism of Action 72
Gilead Sciences, Inc. – Recent Pipeline Updates 74
Gilead Sciences, Inc. - Dormant Projects 93
Gilead Sciences, Inc. - Discontinued Pipeline Products 96
Discontinued Pipeline Product Profiles 96
Gilead Sciences, Inc. – Company Statement 99
Gilead Sciences, Inc. – Locations And Subsidiaries 102
Head Office 102
Other Locations & Subsidiaries 102
Gilead Sciences, Inc., Recent Developments 106
Gilead Sciences, Inc.- Press Release 106
Financial Deals Landscape 133
Gilead Sciences, Inc., Deals Summary 133
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deal Details 139
Asset Transactions 139
Venture Financing 143
Partnerships 146
Licensing Agreements 163
Equity Offering 212
Debt Offering 214
Asset Transactions 230
Acquisition 233
Appendix 255
Methodology 255
Coverage 255
Secondary Research 255
Primary Research 255
Expert Panel Validation 255
Contact Us 256
Disclaimer 256
List of TablesList of Tables
Gilead Sciences, Inc., Key Information 12
Gilead Sciences, Inc., Key Facts 12
Gilead Sciences, Inc. – Pipeline by Indication, 2012 15
Gilead Sciences, Inc. – Pipeline by Stage of Development, 2012 17
Gilead Sciences, Inc. – Monotherapy Products in Pipeline, 2012 18
Gilead Sciences, Inc. – Combination Treatment Modalities in Pipeline, 2012 19
Gilead Sciences, Inc. – Filed, 2012 20
Gilead Sciences, Inc. – Phase III, 2012 21
Gilead Sciences, Inc. – Phase II, 2012 22
Gilead Sciences, Inc. – Phase I, 2012 24
Gilead Sciences, Inc. – Pipeline By Therapeutic Class, 2012 73
Gilead Sciences, Inc. - Pipeline By Target, 2012 75
Gilead Sciences, Inc. – Pipeline By Route of Administration, 2012 76
Gilead Sciences, Inc. – Pipeline Products By Mechanism of Action, 2012 78
Gilead Sciences, Inc. – Recent Pipeline Updates, 2012 79
Gilead Sciences, Inc. - Dormant Developmental Projects,2012 98
Gilead Sciences, Inc. - Discontinued Pipeline Products, 2012 101
Gilead Sciences, Inc., Other Locations 107
Gilead Sciences, Inc., Subsidiaries 108
Gilead Sciences, Inc., Deals Summary 138
Gilead Sciences To Acquire Oceanside Clinical Plant From Genentech 144
Gilead Sciences And Royalty Pharma Acquire Royalty Interest Of Emtriva From Emory University 146
Achillion Pharma Raises $35 Million In Series C2 Financing 148
Gilead Sciences Enters Into Licensing Agreement With CONRAD And IPM 151
Adimab Enters Into Co-Development Agreement With Gilead Sciences 152
Gilead Sciences Enters Into Research Collaboration With Yale School of Medicine 154
Selcia Enters Into Collaboration With Gilead Sciences 156
Gilead Sciences Enter Into An Agreement With Merck 157
Gilead Sciences Enters Into Research Collaboration With Gladstone Institute 158
Gilead Sciences Enters Into An Agreement With Bristol-Myers Squibb 159
Bristol-Myers Squibb And Gilead Sciences Enters Into An Agreement For ATRIPLA 160
Gilead Sciences Enters Into Distribution Agreement With Merck & Co. 162
Praecis Pharma Enters Into Technology Transfer Agreement With Gilead Sciences 163
GlaxoSmithKline Signs An Agreement With Myogen 164
Bristol-Myers Squibb Enters Into Joint Venture With Gilead Sciences 165
Genelabs Technologies Enters Into Collaboration Agreement With Gilead Sciences 167
Medarex Amends Collaboration And Licensing Agreement With Gilead Sciences 168
Japan Tobacco Enters Into Licensing Agreement With Gilead Sciences For cobicistat 169
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 170
Bristol-Myers Squibb Enters Into Licensing Agreement With Gilead Sciences 171
Gilead Sciences Enters Into Licensing Agreement With GlobeImmune 172
Boehringer Ingelheim Enters Into Licensing Agreement With Gilead Sciences For BI 224436 173
Gilead Sciences Extends Licensing Agreement With Hetero Drugs For Tenofovir, Elvitegravir, Cobicistat And Quad 174
Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 176
Gilead Sciences Extends Licensing Agreement With Ranbaxy Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 178
Gilead Sciences Extends Licensing Agreement With Strides Arcolab For Tenofovir, Elvitegravir, Cobicistat And Quad 180
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 182
Gilead Sciences Enters Into Licensing And Collaboration Agreement With MicroDose For MDT-637 183
Yuhan Enters Into Licensing Agreement With Gilead Sciences For Viread 185
GlaxoSmithKline Enters Into Licensing Agreement With Gilead Sciences 186
Gilead Sciences Enters Into Licensing Agreement With Tibotec Pharma 187
Gilead Sciences Amends Licensing Agreement With Aspen Pharmacare 189
Gilead Sciences Enters Into Licensing Agreement With LG Life Sciences 190
Gilead Sciences Enters Into Licensing Agreement With Parion Sciences 192
Gilead Sciences Enters Into Licensing Agreement With Alkem Labs 194
Gilead Sciences Enters Into Licensing Agreement With Medchem 195
Gilead Sciences Enters Into Licensing Agreement With Matrix Labs 196
Gilead Sciences Enters Into Licensing Agreement With Ranbaxy Labs 197
Gilead Sciences Enters Into Licensing Agreement With FDC 198
Gilead Sciences Enters Into Licensing Agreement With Aurobindo Pharma 199
Gilead Sciences Enters Into Licensing Agreement With Shasun Chemicals & Drugs 200
J. B. Chemicals Enters Into Licensing Agreement With Gilead Sciences 201
Gilead Sciences Enters Into Licensing Agreement With Strides Arcolab 202
Gilead Sciences Enters Into Licensing Agreement With Hetero Drugs 203
Gilead Sciences Enters Into Licensing Agreement With Emcure Pharma 204
Diatos Enters Into Licensing Agreement With Gilead Sciences 205
GlaxoSmithKline Enters Into Licensing Agreement With Myogen 207
Gilead Sciences Amends Licensing Agreement With Roche For Tamiflu 208
Gilead Sciences Enters Into Licensing And Distribution Agreement With Aspen Pharmacare 209
Gilead Sciences Enter Into Licensing Agreement With Japan Tobacco 211
Achillion Pharma Enters Into Licensing Agreement with Gilead Sciences 213
Gilead Sciences Amends Licensing Agreement With IOCB And Rega Stichting 214
CyDex Pharma Enters Into Licensing Agreement With Gilead Sciences 215
4 AZA Bioscience Enters Into Licensing Agreement With Gilead Sciences 216
Corus Pharma Completes Private Placement Of $25 Million 217
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2014 For $750 Million 219
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2016 For $700 Million 221
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2021 For $1.25 Billion 223
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2041 For $1 Billion 225
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2021 For $1,000 Million 227
Gilead Sciences Completes Private Placement Of 1% Senior Notes For $1,100 Million 229
Gilead Sciences Completes Private Placement Of 1.625% Senior Notes For $1,100 Million 231
Gilead Sciences Completes Private Placement Of Convertible Senior Notes Due 2011 For $650 Million 233
Gilead Sciences Completes Private Placement Of Convertible Senior Notes Due 2013 For $650 Million 234
Galen Acquires DaunoXome, Chemotherapy Agent, From Gilead Sciences 235
Graceway Pharma Acquires Licensing Rights From Gilead Sciences 237
Gilead Sciences Completes Acquisition Of Pharmasset For $11.2 Billion 238
Gilead Sciences Acquires Calistoga Pharma 241
Gilead Sciences Acquires Arresto Biosciences 244
Gilead Sciences Acquires CGI Pharma 246
Gilead Sciences Acquires CV Therapeutics 250
Gilead Sciences Acquires Navitas Assets 252
Gilead Sciences Acquires Nycomed Limited 253
Gilead Sciences Acquires Myogen 254
Gilead Sciences Acquires Raylo Chemicals From Degussa 256
Gilead Sciences Acquires Corus Pharma 258
List of FiguresList of Figures
Gilead Sciences, Inc. – Pipeline by Indication, 2012 14
Gilead Sciences, Inc. – Pipeline by Stage of Development, 2012 17
Gilead Sciences, Inc. – Monotherapy Products in Pipeline, 2012 18
Gilead Sciences, Inc. – Combination Treatment Modalities in Pipeline, 2012 19
Gilead Sciences, Inc. – Pipeline By Therapeutic Class, 2012 72
Gilead Sciences, Inc. - Pipeline By Target, 2012 74
Gilead Sciences, Inc. – Pipeline By Route of Administration, 2012 76
Gilead Sciences, Inc. - Pipeline Products By Mechanism of Action, 2012 77
| Title |
Date |
Price |
|
|
Jan 2013 |
$2000.00 |
|
| By Netscribes (India) Pvt. Ltd. |
| |
|
May 2012 |
$0.00 |
| Medical Devices Market in Russia 2009-2013 |
| By Infiniti Research Ltd |
| Medical devices comprise surgical equipment & appliances, diagnostic devices, X-ray, ophthalmic equipment, laboratory devices & diagnostics, dental equipment, medical disposables and others.The Russia ...Read More
|
|
Mar 2010 |
$1500.00 |
|
|
Jan 2013 |
$250.00 |
|
|
Jan 2012 |
$250.00 |
|
|
Jan 2010 |
$149.00 |
|
|
Jan 2010 |
$149.00 |
| 2010 U.S. HMO Medical Centers Industry Report |
| By Barnes Reports |
| The U.S HMO Medical Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and 20 ...Read More
|
|
Jan 2010 |
$149.00 |
|
|
Oct 2009 |
$149.00 |
|
|
Jan 2010 |
$149.00 |
|
| |
|
|
|
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9425069161
|
|
|
| |
|
| |
|
|
|
